ADC Therapeutics SA Common Shares (NY:ADCT)

1.230 +0.100 (+8.85%)

Delayed Quote Updated: 3:20 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about ADC Therapeutics SA Common Shares

< Previous 1 2 3 4 5 6 7 8 9 Next >

ADC Therapeutics Announces Receipt of $50 Million Second Tranche of Convertible Credit Facility with Deerfield

May 17, 2021

From ADC Therapeutics SA

Via Business Wire

ADC Therapeutics Announces Online Publication of LOTIS-2 Results in The Lancet Oncology

May 12, 2021

From ADC Therapeutics SA

Via Business Wire

ADC Therapeutics SA (ADCT) Q1 2021 Earnings Call Transcript ↗

May 06, 2021

ADCT earnings call for the period ending March 31, 2021.

Via The Motley Fool

Topics Earnings

ADC Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Updates

May 06, 2021

From ADC Therapeutics SA

Via Business Wire

Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge ↗

May 01, 2021

Biopharma stocks experienced volatility in the week ended April 30, as stocks reacted to earnings, data readouts and a handful of FDA decisions. Earnings prints from big name...

Via Benzinga

The Daily Biotech Pulse: CorMedix Slumps On Delay In Resubmission of DefenCath NDA, Apellis Awaits FDA Decision, Vera Therapeutics Debuts ↗

May 14, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 13) Alexion Pharmaceuticals, Inc...

Via Benzinga

The Daily Biotech Pulse: Minerva, InflaRx Report Positive Data Readouts, Lucira COVID-19 Test Kit Available On Amazon, Decision Day For Heron ↗

May 12, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 11) HOOKIPA Pharma Inc. (NASDAQ...

Via Benzinga

The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom ↗

May 06, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 5) AbbVie Inc. (NYSE: ABBV)...

Via Benzinga

ADC Therapeutics’ ZYNLONTA™ (loncastuximab tesirine-lpyl) Added to National Comprehensive Cancer Network® Clinical Practice Guidelines in Oncology for B-cell Lymphomas

May 05, 2021

From ADC Therapeutics SA

Via Business Wire

ADC Therapeutics to Participate in May Investor Conferences

May 04, 2021

From ADC Therapeutics SA

Via Business Wire

Attention Biotech Investors: Mark Your Calendar For May PDUFA Dates ↗

May 01, 2021

Following a mixed month in April, the Food and Drug Administration sets out to review another slate of drugs in May. ACADIA Pharmaceuticals Inc.'s (NASDAQ: ACAD) Nuplazid...

Via Benzinga

ADC Therapeutics to Host First Quarter 2021 Financial Results Conference Call on May 6, 2021

April 29, 2021

From ADC Therapeutics SA

Via Business Wire

ADC Therapeutics Stock Jumps On Scoring First FDA Approval For DLBCL Treatment ↗

April 26, 2021

ADC Therapeutics SA (NYSE: ADCT) has scored an FDA approval for Zynlonta, formerly known as loncastuximab tesirine, as a solo treatment for adult patients...

Via Benzinga

ADC Therapeutics Announces FDA Approval of ZYNLONTA™ (loncastuximab tesirine-lpyl) in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

April 23, 2021

From ADC Therapeutics SA

Via Business Wire

The Daily Biotech Pulse: Moderna To Supply Variant-Specific Vaccine To Israel, Roche's Diagnostics Business Comes to Rescue ↗

April 21, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 20) Alexion Pharmaceuticals,...

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.